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Background: Pulmonary impairment in patients suﬀ ering ulcerative colitis (UC) has been suggested by several investigators using 
standard pulmonary function tests (PFTs). Th is changes in pulmonary function associated with minimal respiratory symptoms have 
been documented, especially in patients with active disease. Th e aim of this prospective study was to determine airway resistance 
and lung volumes in patients with UC who have no respiratory symptoms in comparisons to a healthy control group. Materials and 
Methods: We evaluated a total of 30 patients with UC by means of spirometry, body plethysmography, and impulse oscillometry. 
Th e patients were not complaining of any pulmonary symptoms and did not present any history of previous respiratory diseases. As 
controls we examined 30 healthy subjects matched for gender, age, and smoking status. Th e relationship between PFT, lung volume, 
and airway resistance; and the activity, localization, and duration of the UC disease were analyzed. Results: Th ere was a signiﬁ cant 
diﬀ erence between airway resistances (kPa/L/s) measured by body plethysmography in patients with UC and those of the controls 
(R5hz; 0.60 ± 0.44 vs. 0.39 ± 0.13; P < 0.001) and R20hz (0.37 ± 0.19 vs. 0.29 ± 0.1, P = 0.02). Th ere were no correlation between PFT, 
airway resistance and site and scoring activity (P > 0.05). Conclusion: Despite the lack of pulmonary symptoms, increased airway 
resistance was found in UC patients. We also have not found correlation between PFT, lung volume and airway resistance values 
and scoring of UC activity.
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with normal baseline lung function had been reported.[8] 
Some patients might have abnormal pulmonary function 
and alveolar lymphocytosis in the absence of symptoms 
referring to respiratory system, and may not refer to a 
pulmonary physician.[3]
The association between IBD and pulmonary involvement 
has not been well-clarified and not emphasized; 
therefore, clinicians may not pay aĴ ention to pulmonary 
involvement in the IBD patients:[9] Furthermore, some 
observations suggest that an infl ammation exists in the 
airways that is not detectable by routine pulmonary 
function tests (PFTs).[6,10] Body plethysmography is the 
gold standard for assessment of airway resistance. This 
method measures resistance of the entire airway from the 
mouth to the “average” alveolus. Impulse oscillometry 
(IO) is an alternative method, which measures airway 
resistance by sending a low energy sound wave produced 
by a loudspeaker into the lungs of a spontaneously 
breathing subject and looking for changes in fl ow in 
response to the dilatory eﬀ ect of the applied energy.[11]
Although previous studies evaluated the relationship 
between UC and PFT, but no studies consider all 
INTRODUCTION
The chronic inflammatory bowel disease (IBD), 
ulcerative colitis (UC) which is a diffuse process, 
involving the superfi cial mucosa of the colon is one 
of the common morbidities affecting many people 
throughout the world.[1] Although, the etiology of UC 
is unknown, genetic and environmental factors are 
thought to be responsible in the pathophysiology of 
UC.[2] Despite the known systemic manifestation of 
UC and a number of reports linking lung disease and 
UC, this association is oĞ en overlooked as an extra-
intestinal manifestation of UC.[3-5] IBD is associated with 
a variety of extra-intestinal manifestations, although 
the lungs are not generally considered as a common 
site of involvement.[4,6] Some observations suggest that 
mucosal infl ammation of the gastrointestinal tract can 
spill over to the airways.[5,7] Involvement of airway’s 
epithelium is sometimes seen in association with UC, 
raising the possibility of a systemic mechanism aﬀ ecting 
both bronchial and colonic epithelium.[7] An increased 
bronchial hyper-responsiveness in patients with IBD 
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above tests (IO, body plethysmography and spirometry) 
in asymptomatic patients. Therefore, the purpose of this 
study was to evaluate possible changes in airway resistance 
of patients suﬀ ering UC with no pulmonary symptoms. We 
used both body plethysmography and IO to determine the 
airway resistance and compare it with control group.
MATERIALS AND METHODS
Ethical CommiĴ ee of the institution approved the research 
protocol (Research project Number: 386393) and a wriĴ en 
consent was signed by the participants or the gradients. 
Thirty consecutive suﬀ ering UC patients referring to the 
Department of Gastroenterology of the University Hospitals 
of Isfahan, Iran, were included in the study, if:
1. The diagnosis of UC established by the characteristic 
history coupled with a typical endoscopic appearance of 
the mucosa and confi rmatory histology seen on colonic 
biopsy.[12]
2. They did not present any chronic pulmonary symptoms, 
including: chronic cough, phlegm, or dyspnea and 
did not represent any history of chronic lung diseases 
such as: Asthma, tuberculosis, chronic bronchitis, etc. 
Since mild obstructive lung disease in UC patients 
was aĴ ributed to smoking and allergy,[13] smokers and 
asthmatic patients were not included. Furthermore, 
patients with occupation in high-risk jobs for respiratory 
system were not included.
The patients have been treated with mesalazine (9 patients), 
sulfasalazine (6 patients), Asacol (4 patients), azathioprine + 
mesalazine (9 patients), azathioprine + sulfasalazine 
(1 patient) and azathioprine + Asacol (1 patients). None of 
them have received corticosteroid or methotrexate.
A group of 30 healthy age and sex matched individuals 
referred for checkup were enrolled as controls. The 
members of this group did not have any of the symptoms 
to be suspected for UC.
The disease was either active or quiescent. Disease activity 
in UC patients was evaluated with the simple clinical 
colitis activity index (SCCAI), as described by Walmsley 
et al.[14] Evaluation of disease activity was done at the time 
of pulmonary function measurements. In SCCAI, bowel 
movements per day, blood in stool, fever, tachycardia, 
anemia, erythrocyte sedimentation rate, and endoscopic 
appearance were evaluated. In study that was performed 
by Alavi Foumani et al.[10] UC activity was assessed by 
Rachmilewitz clinical activity index. Index ≥4 and index <4 
were recognized as active and inactive respectively.
All patients underwent for spirometry and body 
plethysmography and IO tests as followings:
Spirometry and body plethysmography
Lung volumes and subdivision indices were measured, 
using a body plethysmography machine (ZAN500 bodybox; 
nSpire Health, Inc., UK) according to the published standards 
and criteria.[15,16] AĞ er obtaining spirometric measurements, 
the subject was allowed to rest for 5 min before proceeding 
to the measurement of lung subdivisions. Briefl y, the subject 
was taught the panting technique, while breathing through 
the mouthpiece of the body plethysmograph. The door 
was then closed and the measurements including residual 
volume (RV), functional residual capacity (FRC), and total 
lung capacity (TLC) were made. The results were corrected 
for body temperature, pressure, saturation automatically by 
the body-box soĞ ware. All of the measurements were made 
by one trained technician. The output report of each subject 
was scrutinized qualitatively by one pulmonary physician 
(B.A.) before inclusion for statistical analysis.
Forced oscillation technique
The equipment used for IO (IO Jaeger, Würtzburg, Germany) 
consisted of an impulse generator (a loudspeaker), a 
pneumotachograph, and a pressure transducer. The impulse 
interval was set at the default level of 0.33 s with a pulse 
length of 45 m. The superimposed pressure oscillations during 
normal volume spontaneous breathing are composed of 
several frequencies, allowing the assessment of resistance and 
reactance at several frequencies simultaneously. The frequency 
range of the signal was from 0 to 30 Hz, and we recorded R and 
X at 5 and 25 Hz.[17] we used two methods to improve accuracy 
of measurement and avoid over and under estimation. This is 
useful especially in subjects without good cooperation.
Statistical analysis
Data were collected in a checklist. Statistical analysis was 
performed using the statistical package SPSS version 16 (SPSS 
Inc., Chicago, IL, USA) soĞ ware. Data were expressed as 
mean ± standard deviation the Mann-Whitney test was used 
to assess diﬀ erences in the laboratory parameters between 
the groups, and Spearman’s correlation was used to analyze 
the correlation between the parameters. All the P values were 
two tailed: P < 0.05 were considered as statistically signifi cant.
RESULTS
Demographic characteristics of case and control groups 
have been presented in [Table 1].
Table 1: Demographic characteristics of patients 
with UC and controls (mean ± SD)
Variable UC Controls P value
Mean age, year (mean ± SD) 36.06±10.19 36.2±10.63 0.48
Male/female 12/18 12/18
BMI (kg/m2) (mean ± SD) 24.6±4.2 26±3.86 0.09
BMI = Body mass index; UC = Ulcerative colitis; SD = Standard deviation
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Pulmonary function tests were abnormal in 16 of 30 patients. 
Most common fi nding was decrease of forced expiratory 
fl ow (FEF) 25-75 (FEF 25-75 <60% of predicted value based 
on sex, age and height). There was a signifi cant diﬀ erence 
in the airway resistance between the patients with UC and 
control group (P < 0.01) [Table 2].
Mean values of maximal mid expiratory fl ow (MMEF) 25-75 
in case and control groups were 3.28 ± 1.33 and 3.94 ± 1.92, 
respectively with signifi cant statistical diﬀ erence (P = 0.021). 
Mean values of forced expiratory volume in 1 s/forced vital 
capacity (FEV1/FVC) in case and control groups were 82.34 ± 
4.49 and 83.89 ± 2.91 respectively with signifi cant statistical 
diﬀ erence (P = 0.05). Results regarding diﬀ erent variable 
measure as shown in Table 2.
Patients were divided to three groups based on site of 
bowel disease: LeĞ  sided colitis (16 patients), pancolitis (8 
patients) and proctosigmoiditis (6 patients). There was no 
signifi cant diﬀ erence between site of colon involvement and 
PFT abnormality (P > 0.05).
Relationship between the airway resistance and the disease 
activity index in UC as shown in [Table 3].
Since all patients were new case of UC, we didn’t investigate 
relationship between duration of bowel disease and PFT.
DISCUSSION
The aim of this prospective study was to determine airway 
resistance and lung volumes in patients with UC who have 
no respiratory symptoms in comparisons to a healthy 
control group. This study was the fi rst study that used both 
IO and body plethysmography to measure airway resistance 
in UC patient.
Respiratory function abnormalities are not uncommon in 
patients with UC.[18-34]
The presence of subclinical pulmonary disease in patients 
with minimal respiratory symptoms had been suggested; 
however, the pulmonary function abnormalities had 
revealed inconsistent results.[15] In fact, some authors could 
not detect diﬀ erences in routine PFT between IBD patients 
and controls, while others suggested various changes, 
including a decrease in gas transfer factor, an increased FRC 
and increased RV during periods of active bowel disease,[20] 
decrease in MMEF rate, and an increased frequency of 
bronchial hyperresponsiveness.[7] The most frequently 
reported fi ndings in UC are decrease of FEV1/FVC and TLC, 
increase in RV and FRC.[17] However, such changes have 
been thought to appear, especially during exacerbations of 
underlying UC.[15] Douglas et al. found PFT abnormalities in 
32% of patients with IBD and decreased lung transfer factor 
in 16%.[20] One previous study stated that the most prevalent 
abnormalities in lung function are decrease in diﬀ using 
capacity and increase in RV/TLC ratio.[8] This might mean 
that a restrictive pulmonary impairment is predominant in 
UC patients. This observation is not supported in our study.
In our study, in a group of UC patients obviously with less 
severe disease, a mild and statistically signifi cant reduction 
of FEF 25-75 in patients with UC was found in comparison 
with the control group, the fi ndings are less concerning 
than those suggested by the mentioned authors. However, 
our study revealed that even in such a UC population 
with less severe disease and no respiratory symptoms 
increased airway resistance can be detected by both body 
plethysmography and IO. Interestingly in our study, PFT 
and airway resistance abnormalities were not correlated 
with scoring of disease activity, meaning that pulmonary 
involvement is independent of the bowel disease activity. The 
main question addressed by this study was whether airway 
resistance was aﬀ ected in patients with UC. The main fi nding 
was that UC is indeed accompanied by increased airway 
Table 2: Pulmonary function tests of patients with UC 
and controls
Variable UC Controls P value
FVC (L) 3.85±1.08 4.05±0.9 0.23
FEV1 (L) 3.18±0.94 3.39±0.76 0.17
FEV1/FVC 82.34±4.49 83.89±2.91 0.05
FEF 25-75% (L/s) 3.38±1.33 3.94±1.22 0.02
RV 2.9±0.82 2.13±0.95 0.19
TLC 6.04±1.4 6.15±0.97 0.36
Speciﬁ c airway resistance (SRaw) 1.1±0.31 0.86±0.16 0.00
Total airway resistance (SRaw) 0.34±0.1 0.86±0.16 0.00
R5hz (kPa/L/s) 0.60±0.44 0.39±0.13 0.00
R20hz (kPa/L/s) 0.37±0.19 0.29±0.1 0.02
X5hz (kPa/L/s) −0.26±0.39 −0.29±0.1 0.07
Data are expressed as mean ± SD. P < 0.05 was considered signifi cant. FVC = Forced 
vital capacity; FEV1 = Forced expiratory volume in 1 s; RV = Residual volume; TLC = 
Total lung capacity; R = Resistance; SD = Standard deviation; UC = Ulcerative colitis; 
FEF = Forced expiratory fl ow
Table 3: Correlations with scoring activity of UC with 
pulmonary function tests
Variable R value P value
FVC (L) −0.76 0.44
FEV1 (L) −0.52 0.60
FEV1/FVC −0.30 0.76
FEF 25–75% (L/s) −0.28 0.77
Raw −0.30 0.76
SRaw −0.72 0.47
R5hz (kPa/L/s) −0.89 0.37
R20hz (kPa/L/s) −0.78 0.43
X5hz (kPa/L/s) −0.94 0.06
Comparison between ulcerative colitis patients and controls with Mann-Whitney test. 
UC = Ulcerative colitis; FVC = Forced vital capacity; FEV1 = Forced expiratory volume 
in 1 s; SD = Standard deviation; FEF = Forced expiratory fl ow
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resistance by IO and body plethysmography. We found 
that patients with UC showed increased R5, specifi c airway 
resistance despite their normal baseline spirometry values. 
Contrarily, no signifi cant change was found in spirometry 
values between patients and control subjects, a finding 
suggesting t that increased resistance is an earlier fi nding 
disclosing pulmonary involvement in UC. In another study[10] 
the most common abnormal PFTs in UC patients were air 
trapping (increase of RV/TLC) and small airway obstructive 
paĴ ern (decrease of FEF 25-75). Lung involvement in UC 
also presented with high-resolution computed tomography 
abnormalities up to 50% of patients in a study.[35]
In our study, all patients were new case of UC and therefore, 
we didn’t investigate relationship between duration of bowel 
disease and PFT. In another study,[10] there was a signifi cant 
relationship between small airway obstructive paĴ ern and 
duration of UC and no relationship was noticed between other 
pulmonary disorders and severity, activity, and duration of UC.
Pulmonary involvement seems to be a more frequent extra-
intestinal manifestation of UC than thus far supposed. The 
causes or confounding factors are uncertain.
CONCLUSION
This study has shown that there is increased airway 
resistance and also dysfunction of the small airways in 
patients with UC despite their normal PFTs. However, 
further studies that include transbronchial biopsies are 
needed to verify the precise nature of our observations.[3]
We suggest that all patients with UC should be regularly 
evaluated for possible pulmonary involvement.
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